Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Q3 2025 value amounting to $90.7 million.

  • Arcutis Biotherapeutics' Operating Expenses rose 819.84% to $90.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $356.2 million, marking a year-over-year increase of 1108.18%. This contributed to the annual value of $324.9 million for FY2024, which is 805.83% up from last year.
  • As of Q3 2025, Arcutis Biotherapeutics' Operating Expenses stood at $90.7 million, which was up 819.84% from $96.1 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' 5-year Operating Expenses high stood at $105.5 million for Q3 2022, and its period low was $36.1 million during Q1 2021.
  • Moreover, its 5-year median value for Operating Expenses was $75.0 million (2023), whereas its average is $74.5 million.
  • In the last 5 years, Arcutis Biotherapeutics' Operating Expenses soared by 8478.75% in 2022 and then crashed by 2887.94% in 2023.
  • Over the past 5 years, Arcutis Biotherapeutics' Operating Expenses (Quarter) stood at $71.3 million in 2021, then rose by 0.14% to $71.4 million in 2022, then grew by 4.64% to $74.7 million in 2023, then grew by 5.75% to $79.0 million in 2024, then grew by 14.81% to $90.7 million in 2025.
  • Its Operating Expenses stands at $90.7 million for Q3 2025, versus $96.1 million for Q2 2025 and $90.4 million for Q1 2025.